相似文献
1
Biomarkers of inflammatory bowel disease.
Dis Markers. 2014;2014:710915. doi: 10.1155/2014/710915. Epub 2014 May 19.
2
Serological markers in diagnosis of pediatric inflammatory bowel disease and as predictors for early tumor necrosis factor blocker therapy.
Scand J Gastroenterol. 2017 Apr;52(4):414-419. doi: 10.1080/00365521.2016.1259653. Epub 2016 Nov 25.
3
Fecal S100A12 and fecal calprotectin as noninvasive markers for inflammatory bowel disease in children.
Inflamm Bowel Dis. 2008 Mar;14(3):359-66. doi: 10.1002/ibd.20336.
4
Discriminating IBD from IBS: comparison of the test performance of fecal markers, blood leukocytes, CRP, and IBD antibodies.
Inflamm Bowel Dis. 2008 Jan;14(1):32-9. doi: 10.1002/ibd.20275.
5
Molecular Analysis of Inflammatory Bowel Disease: Clinically Useful Tools for Diagnosis, Response Prediction, and Monitoring of Targeted Therapy.
Mol Diagn Ther. 2015 Jun;19(3):141-58. doi: 10.1007/s40291-015-0142-7.
6
Questions and answers on the role of fecal lactoferrin as a biological marker in inflammatory bowel disease.
Inflamm Bowel Dis. 2009 Nov;15(11):1746-54. doi: 10.1002/ibd.20920.
7
Emerging Biomarkers for the Diagnosis and Monitoring of Inflammatory Bowel Diseases.
Inflamm Bowel Dis. 2016 Aug;22(8):2016-22. doi: 10.1097/MIB.0000000000000836.
8
Approaches to Integrating Biomarkers Into Clinical Trials and Care Pathways as Targets for the Treatment of Inflammatory Bowel Diseases.
Gastroenterology. 2019 Oct;157(4):1032-1043.e1. doi: 10.1053/j.gastro.2019.06.018. Epub 2019 Jun 19.
9
Biological markers in inflammatory bowel disease: practical consideration for clinicians.
Gastroenterol Clin Biol. 2009 Jun;33 Suppl 3:S158-73. doi: 10.1016/S0399-8320(09)73151-3.
10
Biomarkers of Inflammation in Inflammatory Bowel Disease.
Gastroenterology. 2015 Oct;149(5):1275-1285.e2. doi: 10.1053/j.gastro.2015.07.003. Epub 2015 Jul 9.
引用本文的文献
1
Risk factors affecting relapse after discontinuation of biologics in children with Crohn's disease who maintained deep remission.
Front Pediatr. 2024 Oct 7;12:1479619. doi: 10.3389/fped.2024.1479619. eCollection 2024.
2
Hydrogen gas and the gut microbiota are potential biomarkers for the development of experimental colitis in mice.
Gut Microbiome (Camb). 2023 Nov 6;5:e3. doi: 10.1017/gmb.2023.17. eCollection 2024.
3
Precision Medicine in Inflammatory Bowel Disease: A Spotlight on Emerging Molecular Biomarkers.
Biomedicines. 2024 Jul 8;12(7):1520. doi: 10.3390/biomedicines12071520.
4
Diagnostic Procedures for Inflammatory Bowel Disease: Laboratory, Endoscopy, Pathology, Imaging, and Beyond.
Diagnostics (Basel). 2024 Jun 28;14(13):1384. doi: 10.3390/diagnostics14131384.
5
Recent Trends in Non-Invasive Methods of Diagnosis and Evaluation of Inflammatory Bowel Disease: A Short Review.
Int J Mol Sci. 2024 Feb 8;25(4):2077. doi: 10.3390/ijms25042077.
6
Platelet/Albumin ratio and plateletcrit levels are potential new biomarkers for assessing endoscopic inflammatory bowel disease severity.
BMC Gastroenterol. 2023 Nov 14;23(1):393. doi: 10.1186/s12876-023-03043-4.
7
Correlation analysis of serum levels of H19 and CRP levels and ulcerative colitis.
J Med Biochem. 2023 Aug 25;42(3):420-426. doi: 10.5937/jomb0-41359.
8
Quality of Life (QoL) in Patients with Chronic Inflammatory Bowel Diseases: How Much Better with Biological Drugs?
J Pers Med. 2023 Jun 2;13(6):947. doi: 10.3390/jpm13060947.
9
Performance of Machine Learning Algorithms for Predicting Disease Activity in Inflammatory Bowel Disease.
Inflammation. 2023 Aug;46(4):1561-1574. doi: 10.1007/s10753-023-01827-0. Epub 2023 May 12.
10
Application of Procalcitonin for the Rapid Diagnosis of Infection in Patients with Inflammatory Bowel Disease.
Diagnostics (Basel). 2022 Dec 9;12(12):3108. doi: 10.3390/diagnostics12123108.
本文引用的文献
1
Diagnostic yield of endoscopy in patients with abdominal complaints: incremental value of faecal calprotectin on guidelines of appropriateness.
BMC Gastroenterol. 2014 Mar 29;14:57. doi: 10.1186/1471-230X-14-57.
2
Faecal calprotectin testing for differentiating amongst inflammatory and non-inflammatory bowel diseases: systematic review and economic evaluation.
Health Technol Assess. 2013 Nov;17(55):xv-xix, 1-211. doi: 10.3310/hta17550.
3
Neopterin is a novel reliable fecal marker as accurate as calprotectin for predicting endoscopic disease activity in patients with inflammatory bowel diseases.
Inflamm Bowel Dis. 2013 Apr;19(5):1043-52. doi: 10.1097/MIB.0b013e3182807577.
4
Nitric oxide as a potential biomarker in inflammatory bowel disease.
Bosn J Basic Med Sci. 2013 Feb;13(1):5-9. doi: 10.17305/bjbms.2013.2402.
5
A random urine test can identify patients at risk of mesalamine non-adherence: a prospective study.
Am J Gastroenterol. 2013 Feb;108(2):249-55. doi: 10.1038/ajg.2012.419. Epub 2013 Jan 8.
6
Lectin-based immunoassay for aberrant IgG glycosylation as the biomarker for Crohn's disease.
Inflamm Bowel Dis. 2013 Feb;19(2):321-31. doi: 10.1097/MIB.0b013e318280eade.
7
Indoleamine 2,3 dioxygenase in intestinal disease.
Curr Opin Gastroenterol. 2013 Mar;29(2):146-52. doi: 10.1097/MOG.0b013e32835c9cb3.
8
Neopterin concentration as an index of disease activity in Crohn's disease and ulcerative colitis.
J Clin Gastroenterol. 2013 Mar;47(3):246-51. doi: 10.1097/MCG.0b013e3182582cdb.
9
Utility of faecal calprotectin analysis in adult inflammatory bowel disease.
World J Gastroenterol. 2012 Dec 14;18(46):6782-9. doi: 10.3748/wjg.v18.i46.6782.
10
PDCD4/miR-21 dysregulation in inflammatory bowel disease-associated carcinogenesis.
Virchows Arch. 2013 Jan;462(1):57-63. doi: 10.1007/s00428-012-1345-5. Epub 2012 Dec 8.
Zotero 插件